Last reviewed · How we verify

CAM2029 — Competitive Intelligence Brief

CAM2029 (CAM2029) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor partial agonist (long-acting formulation). Area: Psychiatry / Addiction Medicine.

phase 3 Opioid receptor partial agonist (long-acting formulation) Mu-opioid receptor (partial agonist) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

CAM2029 (CAM2029) — Camurus AB. CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CAM2029 TARGET CAM2029 Camurus AB phase 3 Opioid receptor partial agonist (long-acting formulation) Mu-opioid receptor (partial agonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor partial agonist (long-acting formulation) class)

  1. Camurus AB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAM2029 — Competitive Intelligence Brief. https://druglandscape.com/ci/cam2029. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: